Abstracts tagged "Biomarkers"

Abstract Number: 2677 • ACR Convergence 2024
N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus
Joy Park¹, Lanlan Ji¹, Jorge Cabezas¹, Xiaojing Wang², Bryan Blaker¹, Dilip Rao¹, Aparna Godavarthy¹, Lucero Blaker¹, FNU Ruchi¹, Ioana Coman¹, Nancy Olsen³, Joshua Lewis², Mariko Ishimori⁴, Kyriakos Kirou⁵, Christina Donath¹, Sara Kahlown⁶, Damira Sereda¹, Marlene Marte Furment¹, Sandy Nasr⁷, Sravani Lokineni¹, rosalind Ramsey-Goldman⁸, Michael Weisman⁹, Arthur Weinstein¹⁰, Cynthia Aranow¹¹, Banki Katalin¹², Michael McDermott¹³, Daniel Wallace¹⁴ and Andras Perl¹, ¹SUNY, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Penn State University/Milton S Hershey, Hershey, PA, ⁴Cedars-Sinai Health System, Los Angeles, CA, ⁵Hospital for Special Surgery, New York, NY, ⁶SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ⁷SUNY Upstate University Hospital, syracuse, NY, ⁸Northwestern University, Chicago, IL, ⁹Stanford University, Los Angeles, CA, ¹⁰Georgetown University, Pasadena, CA, ¹¹Feinstein Institutes for Medical Research, New York, NY, ¹²SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ¹³University of Rochester, Rochester, NY, ¹⁴Cedars Sinai, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…
Abstract Number: 0070 • ACR Convergence 2024
Shared and Unique Fecal and Plasma Metabolic Signatures and Increased Inflammatory Markers in Ankylosing Spondylitis, Psoriatic Arthritis and Acute Anterior Uveitis
Sneha Couvillion¹, Javier Flores¹, Sean Davin², Kimberly Ogle², Emma Fale-Olsen², John Davis², Gina Many¹, Carley Shaut², Tammy Martin², Eric Suhler², Atul Deodhar³, James Rosenbaum⁴, Ernesto Nakayasu¹ and Tejpal Gill², ¹PNNL, Richland, WA, ²OHSU, Portland, OR, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Corvus Pharmaceuticals and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Spondyloarthritis (SpA) is a group of immune-mediated inflammatory disorders such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), along with acute anterior uveitis (AAU)…
Abstract Number: 0401 • ACR Convergence 2024
Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
Cora Sears¹, Cassandra Muir¹, Timothy Brandon¹, Polly Ferguson², Colleen Correll³, Margalit Rosenkranz⁴, Kevin Baszis⁵, Tzielan Lee⁶, Edward Oberle⁷, Matthew Stoll⁸, Kathryn Cook⁹, Eyal Muscal¹⁰, Hemalatha Srinivasalu¹¹, Daniel Lovell¹², Sampath Prahalad¹³, Michal Cidon¹⁴, Evan Mulvihill¹⁵, Marisa Klein-Gitelman¹⁶, Daniel Kingsbury¹⁷, Jennifer Cooper¹⁸, Natalie Rosenwasser¹⁹, Erin Treemarcki²⁰, Joyce Chang²¹, Stacey Tarvin²², Heather Walters²³, Michael Shishov²⁴, Lisa Buckley²⁵, Mary Toth²⁶, Ashley Cooper²⁷, Rui Xiao²⁸, Emily Neu²⁹, Melanie Kohlheim³⁰, Jenny Leal³¹, Kweli Archie³², English Holland³³, Miles Holland³⁴, Aamena Hameed³⁵, Asad Khan³⁶, Lynn Murphy³⁷, Sean Murphy³⁸, Justin Neu²⁹, Rachel Richmond³⁹, Dylan Suplee⁴⁰, Theresa Suplee⁴¹, Dawn Wiley⁴² and Pamela Weiss⁴³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Iowa Carver College of Medicine, Iowa City, IA, ³University of Minnesota, Minneapolis, MN, ⁴UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁵Washington Univ in St. Louis School of Medicine, St Louis, MO, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Akron Children's Hospital, Akron, OH, ¹⁰Baylor College of Medicine, Houston, TX, ¹¹Children's National Hospital, Washington, DC, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁴Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁵Nemours/A.I.duPont Hospital for Children, Wilmington, DE, ¹⁶Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁷Legacy Health, Portland, OR, ¹⁸University of Colorado/Children's Hospital Colorado, Aurora, CO, ¹⁹Seattle Children's Hospital, Seattle, WA, ²⁰University of Utah, Salt Lake City, UT, ²¹Boston Children's Hospital, Boston, MA, ²²Indiana University School of Medicine, Indianapolis, IN, ²³Northwell Health, New Hyde Park, NY, ²⁴Phoenix Children's Hospital, Phoenix, AZ, ²⁵Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²⁶Nemours Foundation, Orlando, FL, ²⁷Children's Mercy Kansas City, Kansas City, MO, ²⁸University of Pennsylvania, Philadelphia, PA, ²⁹Parent Partner, Sidney, OH, ³⁰Parent Partner, Granville, OH, ³¹Parent Partner, Columbus, OH, ³²Parent Partner, Philadelphia, PA, ³³Parent Partner, Williamsburg, VA, ³⁴Patient Partner, Williamsburg, VA, ³⁵Parent Partner, Franklin Park, NJ, ³⁶Patient Partner, Franklin Park, NJ, ³⁷Parent Partner, Haddon Heights, NJ, ³⁸Patient Partner, Haddon Heights, NJ, ³⁹Parent Partner, Albuquerque, NM, ⁴⁰Patient Partner, Maple Shade, NJ, ⁴¹Parent Partner, Maple Shade, NJ, ⁴²Parent Partner, Downingtown, PA, ⁴³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Inactive disease is the goal for youth with spondyloarthritis (SpA). Many patients are interested in stopping medications after inactive disease is achieved. The risk…
Abstract Number: 0562 • ACR Convergence 2024
Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study
Lucia Ondrejčáková¹, Adéla Navrátilová², Monika Gregová³, Kristýna Bubová⁴, Tomáš Grega⁵, Ladislav Šenolt⁶, Karel Pavelka⁷ and Lucie Andrés Cerezo⁸, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ²1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁵3Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
Abstract Number: 0685 • ACR Convergence 2024
KL-6 and IL-18 Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Enhancing Prognostic Insights into Early Detection, Progression, Lung Volume Changes,and Mortality Risk
cristiana sieiro santos¹, Miriam Retuerto², Laura Sierra², Sara Calleja Antolín², Elena Bollo de Miguel², Jose Ordas Martínez³, Paula Pérez García², Pedro Baenas², Clara Moriano Morales², Javier de la Calle Lorenzo² and Elvira Díez Álvarez⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in scleroderma, underscoring the critical demand for reliable biomarkers. KL-6 and IL-18, have been…
Abstract Number: 0811 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis
Benjamin Jones¹, Rufei Lu², Andrea Fava³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steven Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Judith James¹³ and Joel Guthridge¹³, ¹Oklahoma State University, Oklahoma City, OK, ²University of California San Francisco, San Bruno, CA, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
Abstract Number: 0915 • ACR Convergence 2024
APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism
Yiming Luo, Lili Liu, Atlas Khan, R. Graham Barr, Elana Bernstein and Krzysztof Kiryluk, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Anti-Beta-2-glycoprotein 1 antibody (anti-B2GP1) is associated with antiphospholipid syndrome (APS), a rare autoimmune disease that causes venous thromboembolism (VTE). APOH, which expresses the B2GP1…
Abstract Number: 1268 • ACR Convergence 2024
Neutrophil Lymphocyte Ratio as a Novel Marker of Skin Disease Activity in Older Children with Juvenile Dermatomyositis
Shreya Swaminathan¹, Nidhi Naik², Susan Shenoi³, Sarah Vandenbergen⁴, Jessica Turnier⁵, Zilan Zheng⁶, Jessica Neely⁶, James Andrews⁷ and Christian Lood⁸, ¹University of Washington, Seattle, ²Seattle children's hospital, Bothell, WA, ³Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Saline, MI, ⁶UCSF, San Francisco, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Washington, Seattle, WA
Background/Purpose: Exaggerated neutrophil activation can lead to inflammation and organ damage in rheumatic diseases, including dermatomyositis (DM). In both juvenile (JDM) and adult DM, markers…
Abstract Number: 1504 • ACR Convergence 2024
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
Emma Neary¹, Carolina Munoz-Grajales², Joan Wither³, Juan Pablo Diaz Martinez³, Michelle Barraclough⁴, Kathleen Bingham³, Roberta Kretzmann³, Maria Carmela Tartaglia⁵, Lesley Ruttan⁶, May Choi⁷, Simone Appenzeller⁸, Sherief Marzouk³, Dennisse Bonilla³, Patti Katz⁹, Dorcas Beaton¹⁰, Robin Green³, Laura Patricia Whittall Garcia³, Dafna Gladman¹¹ and Zahi Touma¹², ¹McGill University, Montreal, QC, Canada, ²UHN/TWH, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The University of Manchester, Manchester, United Kingdom, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, SP, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is an increasingly prevalent neuropsychiatric manifestation in patients with systemic lupus erythematosus (SLE). Although CI has been identified through patient-reported outcomes…
Abstract Number: 1783 • ACR Convergence 2024
Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Understanding the molecular mechanisms of SLE is crucial for developing effective…
Abstract Number: 2070 • ACR Convergence 2024
Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Margherita Giannini¹, Anne-Laure Charles², Julien Blaess³, Rose-Marie Javier⁴, Bernard Geny⁵ and Alain Meyer⁶, ¹UR3072, Physiology Department, University Hospital of Strasbourg, Strasbourg, France, ²UR3072, University of Strasbourg, Strasbourg, France, ³Physiology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁴Rheumatology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁵UR3072, Physiology Department, University Hospital of StrasbourgUniversity Hospital of Strasbourg, STRASBOURG, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In inflammatory myopathies (IM), although several treatments effectively control disease activity, a high proportion of patients display sustained disability (damage). Damage might be reversed…
Abstract Number: 2315 • ACR Convergence 2024
Exploring Antibodies in Psoriatic Arthritis: A Novel Autoimmune Biomarker Discovered
Theo WIRTH¹, Emmanuel Massy², Nathalie Lambert³, Isabelle Auger³, Nathalie Balandraud¹ and Florent Amatore⁴, ¹Department of Rheumatology, Sainte Marguerite Hospital, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France, ²Department of Rheumatology, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ³INSERM UMRs1097, Arthrites autoimmunes, Marseille, Marseille, France, ⁴Department of Dermatology, Nord hospital, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, MARSEILLE 9EME, France
Background/Purpose: Psoriatic arthritis (PsA) can be challenging to diagnose due to the lack of specific biomarkers. Although a few teams have demonstrated the presence of…
Abstract Number: 2505 • ACR Convergence 2024
C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Joao Carlos Batista-Liz¹, Vanesa Calvo-Rio², María Sebastián Mora-Gil³, Ligia Gabrie-Rodriguez⁴, Rafael Gálvez Sánchez⁴, Belén Sevilla-Pérez⁵, José Luis Callejas⁶, María Teresa Leonardo⁷, Ana Peñalba⁷, Javier Narvaez-García⁸, Luis Martín-Penagos⁹, Luis Caminal-Montero¹⁰, PAZ COLLADO¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Esteban Rubio¹⁴, Manuel León Luque¹⁵, Juan María Blanco-Madrigal¹⁶, Eva Galindez-Agirregoikoa¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸, Veronica Pulito-Cueto¹ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Cantabria, Spain, ³Immunopathology Group, IDIVAL, Santander, Spain, ⁴Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ⁷Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Hospital Universitario Severo Ochoa, MADRID, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, ¹⁶Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, ¹⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
Abstract Number: 2689 • ACR Convergence 2024
Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis
Lynn Fussner¹, Ivan Bilic², Carol McAlear³, David Cuthbertson⁴, Jie Cheng⁵, Elise Chen⁵, Markus Weiller², Ulrich Specks⁶ and Peter Merkel³, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Takeda Pharmaceuticals, Vienna, Austria, ³University of Pennsylvania, Philadelphia, PA, ⁴University of South Florida, Tampa, FL, ⁵Takeda Pharmaceuticals, Cambridge, MA, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
Abstract Number: 0075 • ACR Convergence 2024
Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
Darshini Ganatra¹, Omar Cruz Correa¹, Ameth Garrido², Starlee Lively³, Rohan Apurva Machhar⁴, Remy Pollock⁵, Mohit Kapoor⁶ and Dafna Gladman⁷, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³UHN, Toronto, Canada, ⁴Novartis, Mississauga, ON, Canada, ⁵Pfizer, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis linked to psoriasis, a chronic skin and nail disease. PsA is a progressive joint disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].